Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the majority of new drug applications.
Related Posts
Jefferies says the rest of Wall Street is wrong about these stocks it likes
Here are the firm’s contrarian stock picks.
FBI Director Christopher Wray to resign before Trump takes office
President-elect Donald Trump has said he intends to nominate Kash Patel to replace FBI Director Christopher Wray.
Super Micro issues weak guidance, cites ‘economic uncertainty and tariff impacts’
A week after issuing disappointing preliminary results, Super Micro said in its earnings release that it could see an impact from President Trump’s tariffs.